Anti-Human CD5 (Clone UCHT-2) – PE

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This R-PE conjugate is stable when stored at 2-8°C. Do not freeze.

Next Day 2-8°C

Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)

IHC (Frozen)
WB
For specific conjugates of this clone, review literature for suggested application details.

Mouse Anti-Human CD5 (Clone UCHT-2) recognizes Human CD5. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. Anti-Human CD5 recognizes a human T-lymphocyte antigen (Mr 67 kDa).

Anti-Human CD5 can be used in research to study B-lymphocyte subsets or characterization of leukemias and lymphomas.

The CD5 antigen is present on approximately 70% of normal peripheral blood lymphocytes and >90% of all T-lymphocytes. T-lymphocytes in the thymus stain weakly while peripheral T-cells stain strongly. Monocytes, granulocytes and NK cells are not stained.¹ Anti-CD5 also reacts with a distinct subset of normal B-lymphocytes, occasional cells in B-lymphocyte areas of spleen and lymph node, and most Ig+ B-chronic lymphoblastic leukemia (CLL) cells. The CD5 antigen has also been shown to be present on some lymphomas.

CD72

1. Leukocyte Typing VI (1995) Oxford University Press 2. Leukocyte Typing III (1987) Oxford University Press 3. Beverly, P. C. L. et al. (1981) "Protides of the Biological Fluids," Vol. XXIX, Peeters, H. (ed.), Pergamon Press, Oxford, 653 Phycobilliproteins are protected under the following patents: (U.S. patents No. 4,520,110 and 4,542,104, European patent no. 76695, Canadian patent No. 1,179,942 and Australian patent No. 548,440).